All In Biotech

Drug Trial Radar · NCT06134648

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older

Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 646 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

646

Actual

Start

Nov 1, 2023

Primary completion

Feb 27, 2026

Study completion Feb 27, 2026

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and immunogenicity of a single intramuscular (IM) injection of different doses of an respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine candidate, in adult participants aged 60 years and older. In addition, the study will evaluate the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population.

Conditions

  • Respiratory Syncytial Virus Infection
  • Healthy Volunteers
  • Human Metapneumovirus

Interventions

  • RSV/hMPV vaccine candidate Dose LBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

  • RSV/hMPV vaccine candidate Dose ABiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

  • RSV/hMPV vaccine candidate Dose BBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

  • PlaceboBiological

    Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Presence of unsolicited systemic immediate adverse events (AEs)Time frame: Within 30 minutes after primary vaccination
  2. Presence of solicited injection site or systemic reactionsTime frame: Within 7 days after primary vaccination
  3. Presence of unsolicited AEsTime frame: Within 28 days after vaccination
  4. Presence of medically attended adverse events (MAAEs)Time frame: Up to 6 months after primary injection
  5. Presence of serious adverse events (SAEs)Time frame: Up to 6 months after primary injection
  6. Presence of adverse events of special interest (AESIs)Time frame: Up to 6 months after primary injection
  7. Presence of related SAEsTime frame: Throughout study (approximately 24 months)
  8. Presence of related AESIsTime frame: Throughout study (approximately 24 months)
  9. Presence of fatal SAEsTime frame: Throughout study (approximately 24 months)
  10. Presence of out-of-range biological test resultsTime frame: Within 7 days after vaccination
  11. RSV-A serum neutralizing antibody (nAb) titers at pre-vaccination (D01) and 28 days post- primary vaccination (D29) in Phase IIa (Main/Booster Cohort)Time frame: Day 1 and Day 29
  12. hMPV serum nAb titers at pre-vaccination (D01), 28 days post-primary vaccination (D29) in Phase IIa (Main/Booster Cohort)Time frame: Day 1 and Day 29

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research Site Number : 8400017

    Los Alamitos, California

  • Matrix Clinical Research Site Number : 8400011

    Los Angeles, California

  • Peninsula Research Associates Site Number : 8400001

    Rolling Hills Estates, California

  • Suncoast Research Associates, LLC Site Number : 8400002

    Miami, Florida

  • AMR Chicago, Oakbrook Terrace Site Number : 8400019

    Oakbrook Terrace, Illinois

  • Velocity Clinical Research, Sioux City Site Number : 8400012

    Sioux City, Iowa

  • AMR Lexington Site Number : 8400008

    Lexington, Kentucky

  • AMR Kansas City Site Number : 8400014

    Kansas City, Missouri

  • AMR Knoxville Site Number : 8400010

    Knoxville, Tennessee

  • DM Clinical Research - Tomball Site Number : 8400004

    Tomball, Texas

  • Investigational Site Number : 6300002

    Guayama, Puerto Rico

  • Investigational Site Number : 6300001

    San Juan, Puerto Rico

  • Investigational Site Number : 6300003

    San Juan, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.